Skip to content

EBITDA at other companies

Evolent Health, Inc. logo
Evolent Health, Inc.EVH
$10.96M-51.2%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$87.45M-7.9%
McKesson logo
McKessonMCK
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Calculated from The Oncology Institute, Inc.’s reported figures.

$6.5Mebit+
$1.6MDepreciation Depletion & Amortization
=-$4.9M

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s EBITDA?
The Oncology Institute, Inc. (TOI) reported EBITDA of -$4.9M in Q1 2026.
How has The Oncology Institute, Inc.'s EBITDA changed year-over-year?
The Oncology Institute, Inc.'s EBITDA increased by 39.7% year-over-year, from -$8.13M to -$4.9M.
What is the long-term trend for The Oncology Institute, Inc.'s EBITDA?
Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s EBITDA has grown at a -9.0% compound annual growth rate (CAGR), from -$42.52M to -$29.14M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.